| H01620 | |
| H番号 | H01620 |
| 名称 | レイノー症候群 |
| 概要 | Raynaud syndrome (RS) is characterized by episodic digital ischemia induced by cold or emotional stress. Pathophysiologic mechanisms include temporary vasospasm and fixed digital artery obstruction. Although the underlying pathophysiological mechanism is unclear, alterations in activity of the peripheral adrenoceptor have been implicated, specifically an enhanced smooth muscle contraction due to overexpression or hyperactivity of postsynaptic alpha 2 receptors. RS can occur as an isolated entity, historically referred to as Raynaud disease or now primary RS, or in association with other conditions, most frequently the connective tissue diseases (eg, scleroderma [DS:H01492], systemic lupus erythematosus [DS:H00080], rheumatoid arthritis [DS:H00630], and Sjogren's syndrome [DS:H01502]), often referred to as Raynaud phenomenon or secondary RS. The diagnosis is mainly clinical, based on patient descriptions of skin changes. Therapy has been focused on the use of general vasodilation strategies. |
| カテゴリ | 循環器系疾患 |
| ネットワーク | - |
| 病因遺伝子 | - |
| 病原体 | - |
| 環境要因 | - |
| 発癌物質 | - |
| 治療薬 | イソクスプリン塩酸塩 [DR:D01748] デキサメタゾン [DR:D00292] ベタメタゾンリン酸エステルナトリウム [DR:D00972] ヘプロニカート [DR:D01882] ニセリトロール [DR:D01754] ニコモール [DR:D01291] トリアムシノロン [DR:D00385] ベタメタゾン [DR:D00244] プレドニゾロン [DR:D00472] プレドニゾロンコハク酸エステルナトリウム [DR:D01239] メチルプレドニゾロン [DR:D00407] メチルプレドニゾロン酢酸エステル [DR:D00979] ニコチン酸アミド [DR:D00036] |
| コメント | - |
| リンク | ICD-11: BD42 ICD-10: I73.0 MeSH: D011928 |
| 文献 | PMID:23618525 著者 Landry GJ タイトル Current medical and surgical management of Raynaud's syndrome. 雑誌 J Vasc Surg 57:1710-6 (2013) DOI:10.1016/j.jvs.2013.03.012 PMID:25770637 著者 Valdovinos ST, Landry GJ タイトル Raynaud syndrome. 雑誌 Tech Vasc Interv Radiol 17:241-6 (2014) DOI:10.1053/j.tvir.2014.11.004 |